Our influenza.org.nz website is currently down. Read more

Cartoon image of a man showing his arm where he received a vaccination
Disease
Estimated duration of protection from vaccine after receipt of all recommended doses 1,2
Comments

Polio

>99% protected for at least 18 years

Boosters offered to those travelling to at risk countries

Haemophilus influenzae

>9 years to date

Excellent immunogencity observed for this vaccines suggesting long-term protection

Age
Primary doses 1 and 2
Primary dose 3
First booster dose
Additional booster dose(s)
Healthy population

12-15 years

8 weeks apart

-

-

-

16-29 years

8 weeks apart

-

6 months later

-

30-64 years

8 weeks apart

-

6 months later

From 6 months after previous dose

Age
Primary doses 1 and 2
Primary dose 3
First booster dose
Additional booster dose(s)
Increased risk of severe COVID-19 and severely immune compromised

12-15 years

8 weeks apart

Give 8 weeks after dose 2

From 16 years

8 weeks apart

Give 8 weeks after dose 2

4-6 months later

From 6 months after previous dose

Additional groups at increased risk of severe COVID-19

12-15 years

8 weeks apart

-

From 16 years

8 weeks apart

Give 8 weeks after dose 2

4-6 months later

From 6 months after previous dose

Other risk groups
Age
Primary doses 1 and 2
First booster dose
Additional booster dose(s)

Older adults

From 65 years

8 weeks apart

From 6 months after previous dose

From 6 months after previous dose

Māori or Pacific people

From 50 years

8 weeks apart

From 6 months after previous dose

From 6 months after previous dose

Resident of age or disability care facility

From 16 years

8 weeks apart

From 6 months after previous dose

From 6 months after previous dose

Pregnant people

From 16 years

8 weeks apart

From 6 months after previous dose

From 6 months after previous dose

Healthy population

Age
Primary doses 1 and 2
Primary dose 3
First booster dose
Additional booster dose(s)
12-15 years
8 weeks apart
-
-
-
16-29 years
8 weeks apart
-
6 months later
-
30-64 years
8 weeks apart
-
6 months later
From 6 months after previous dose

Key

-
not required
recommended
eligible, i.e., individuals can consider
not eligible, ie, can be considered off-label and requires prescription and written consent preferred

Comirnaty 10mcg orange cap

Age
Primary doses 1 and 2
Primary dose 3
First booster dose
Additional booster dose(s)
Healthy population

5-11 years

8 weeks apart

-

-

-

Increased risk of severe COVID-19 and severely immune compromised

5-11 years

8 weeks apart

Give 8 weeks after dose 2

-

-

Additional groups at increased risk of severe COVID-19

5-11 years

8 weeks apart

-

-

-

Comirnaty 3mcg maroon cap

Age
Primary doses 1 and 2
Primary dose 3
First booster dose
Additional booster dose(s)
Healthy population

6 months – 4 years

-

-

-

-

Increased risk of severe COVID-19 and severely immune compromised

6 months – 4 years

3 weeks apart

Give 8 weeks after dose 2

-

-

Additional groups at increased risk of severe COVID-19

6 months – 4 years

3 weeks apart

Give 8 weeks after dose 2

-

-